Mead Johnson

Mead Johnson is an American nutrition company whose principal business is the development and sale of infant formula and nutritional products for babies, children, and, in some markets, older students. Its best-known consumer brand is Enfamil, while Nutramigen is associated with specialized infant nutrition. The company’s products have historically been marketed through pediatric and healthcare channels as well as retail distribution, with an emphasis on nutritional science, product specialization, and support for different stages of childhood development. The business traces its origins to Edward Mead Johnson, who had been associated with the founding of Johnson & Johnson. Johnson began an independent venture in the 1890s and reorganized it as Mead Johnson & Company in 1905. The company moved its main manufacturing and operating base to Evansville, Indiana, in 1915, where proximity to agricultural inputs supported the production of its nutritional products. Its early development was closely tied to infant feeding. A major infant formula was introduced in 1910, followed by Dextri-Maltose in 1911. Dextri-Maltose was a carbohydrate-based milk modifier and became an early American infant product to receive clinical approval and physician recommendation. Mead Johnson remained family-led for several decades. After Edward Mead Johnson died in 1934, Lambert Mead Johnson became president and served through 1955. D. Mead Johnson then became the third generation of the family to lead the company. During his tenure, which continued until the Bristol-Myers acquisition, the business expanded substantially, with sales and employment increasing as its product portfolio and manufacturing operations grew. Bristol-Myers agreed to acquire Mead Johnson in the 1960s. The transaction made Mead Johnson part of a large pharmaceutical and consumer-health group, while allowing the nutrition business to continue operating under its own identity. In 2009, Bristol-Myers Squibb separated Mead Johnson through a stock-exchange and public-market transaction. Mead Johnson Nutrition subsequently operated as an independent publicly traded company, with its common shares traded on the New York Stock Exchange. Reckitt Benckiser, now known as Reckitt, announced an agreement to acquire Mead Johnson Nutrition in February 2017 for approximately $16.6 billion, with the proposed consideration structured at $90 per share in cash. The transaction received final regulatory approval in June 2017. After completion, Mead Johnson became part of Reckitt’s Infant Formula and Child Nutrition division and ceased to be an independently traded public company. In 2021, Primavera Capital Group acquired Mead Johnson’s infant-formula and child-nutrition business in China from Reckitt at an implied enterprise value of approximately $2.2 billion. Reckitt retained an 8 percent shareholding in the China business according to the cited reference material. The broader Mead Johnson business remains associated with Reckitt internationally, while ownership and operating arrangements can differ by market. The brand’s historical commercial focus continues to be infant formula, specialized nutrition, and child nutrition rather than general packaged food.

Mead Johnson’s history begins with Edward Mead Johnson, who had been one of the brothers involved in establishing Johnson & Johnson in 1886. In the 1890s, he developed an independent business concerned with digestive aids. The venture was reorganized as Mead Johnson & Company in 1905, establishing the name under which the nutrition business became known. The company moved into infant feeding early in its development. It introduced a major infant formula in 1910 and launched Dextri-Maltose in 1911. Dextri-Maltose was a carbohydrate-based milk modifier intended for infant feeding and became an important early product in the company’s history. The product was described as the first American infant product to receive clinical approval and physician recommendation, helping establish Mead Johnson’s association with medically informed nutrition. In 1915, the company relocated to Evansville, Indiana. The move was connected to access to agricultural raw materials and required the construction of new plants and factories. Evansville became an important center for Mead Johnson’s manufacturing activities and remained closely associated with the company’s industrial history. After Edward Mead Johnson died in 1934, his son Lambert Mead Johnson became president. Lambert led the company until 1955 and is identified as its longest-serving president. D. Mead Johnson, the next family leader, then became chief executive. During his tenure, lasting until the company’s takeover by Bristol-Myers in the late 1960s, annual sales reportedly grew to $131 million and the workforce reached nearly 4,400 employees. Bristol-Myers reached an agreement to acquire Mead Johnson in 1964, and the transaction was completed during the late 1960s. The acquisition valued the business at approximately $240 million and placed Mead Johnson within a larger pharmaceutical and consumer-health organization. Mead Johnson continued to operate as a distinct nutrition business under Bristol-Myers and later Bristol-Myers Squibb. In 2009, Bristol-Myers Squibb announced a separation of Mead Johnson as it refocused on biopharmaceuticals. The separation used a public-market and stock-exchange structure designed to distribute Mead Johnson shares to Bristol-Myers shareholders. Mead Johnson Nutrition thereafter operated as an independent company with its common stock listed on the New York Stock Exchange. Reckitt Benckiser announced in February 2017 that it had agreed to purchase Mead Johnson Nutrition for approximately $16.6 billion. The deal was structured as a cash acquisition at $90 per share and involved a merger subsidiary established by Reckitt. Final regulatory approval was obtained in June 2017. The transaction then closed, making Mead Johnson part of Reckitt’s Infant Formula and Child Nutrition division and ending its status as a separately traded public company. The company’s products have historically been concentrated on infants and children, with most offerings intended for children below seven years of age. Enfaschool extended the company’s stated age range to school-age children and young people under 15. Mead Johnson’s international business has been especially significant in Asia and Latin America, in addition to North America and Europe. In 2021, Primavera Capital Group acquired the Mead Johnson infant-formula and child-nutrition business in China from Reckitt. The transaction was reported at an implied enterprise value of approximately $2.2 billion, with Reckitt retaining an 8 percent interest. The transaction changed the ownership arrangement for the China business while Mead Johnson continued to be associated internationally with Reckitt’s infant and child nutrition activities.

• 2021

  China business sold to Primavera Capital

  [1]Mead Johnsonen.wikipedia.org

  Primavera Capital acquired Mead Johnson’s infant-formula and child-nutrition business in China from Reckitt.

• 2017

  Acquisition by Reckitt

  [1]Mead Johnsonen.wikipedia.org

  Reckitt completed its acquisition of Mead Johnson Nutrition after receiving final regulatory approval.

• 2009

  Separation from Bristol-Myers Squibb

  [1]Mead Johnsonen.wikipedia.org

  Bristol-Myers Squibb separated Mead Johnson Nutrition, creating an independent publicly traded company.

• 1967

  Bristol-Myers acquires Mead Johnson

  [1]Mead Johnsonen.wikipedia.org

  Mead Johnson became majority owned by Bristol-Myers following an acquisition agreed in the mid-1960s.

• 1915

  Operations move to Evansville

  [1]Mead Johnsonen.wikipedia.org

  The company moved to Evansville, Indiana, to improve access to agricultural ingredients and expand manufacturing.

• 1911

  Dextri-Maltose introduced

  [1]Mead Johnsonen.wikipedia.org

  The company introduced Dextri-Maltose, a carbohydrate-based milk modifier for infant feeding.

• 1910

  First major infant formula developed

  [1]Mead Johnsonen.wikipedia.org

  Mead Johnson developed an early major infant-formula product, marking its continuing focus on infant nutrition.

• 1905

  Mead Johnson & Company is established

  [1]Mead Johnsonen.wikipedia.org

  The business was reorganized under the Mead Johnson & Company name.

• 1895

  Edward Mead Johnson starts an independent business

  [1]Mead Johnsonen.wikipedia.org

  Edward Mead Johnson established an independent venture that preceded the formal Mead Johnson company.

Science-led infant and child nutrition, with a premium and specialized positioning built around age-specific formulas, nutritional research, and healthcare-oriented product development.

• Infant formula

  Enfamil

  Enfamil is Mead Johnson’s best-known product family and the principal brand associated with its infant-formula business. It covers formula products intended for different stages and nutritional requirements of infancy and early childhood. The brand has been distributed internationally through retail, healthcare, and specialty nutrition channels.

• Specialized infant formula

  Nutramigen

  Nutramigen is a specialized infant-nutrition line associated with formula designed for babies who require an alternative to standard formulas. It represents Mead Johnson’s emphasis on differentiated and medically oriented nutrition products rather than only mainstream infant feeding.

• Infant feeding product · 1911

  Dextri-Maltose

  Introduced in 1911, Dextri-Maltose was a carbohydrate-based milk modifier used in infant feeding. It was an important early Mead Johnson product and helped establish the company’s reputation in clinically informed infant nutrition.

• School-age nutrition

  Enfaschool

  Enfaschool extended Mead Johnson’s stated target audience beyond infants and young children to students from childhood through early adolescence. It reflects the company’s broader child-nutrition portfolio alongside its core infant-formula business.

• 2021

  Divest China infant-nutrition businessM&A

  Background

  Reckitt restructured ownership of its China infant-formula and child-nutrition operations after acquiring Mead Johnson.

  Action taken

  Primavera Capital Group acquired the Mead Johnson infant-formula and child-nutrition business in China.

  Aftermath

  Reckitt retained an 8 percent shareholding in the China business, while Primavera became the principal owner.

  Implied enterprise value. $2.2 billion (2021)

  Source

• 2017

  Accept Reckitt’s acquisition offerM&A

  Background

  Reckitt Benckiser pursued Mead Johnson to expand its presence in infant formula and child nutrition.

  Action taken

  Reckitt agreed to acquire Mead Johnson Nutrition in a cash transaction structured at $90 per share, with an announced value of approximately $16.6 billion.

  Aftermath

  The merger closed in June 2017 after final regulatory approval. Mead Johnson became part of Reckitt’s Infant Formula and Child Nutrition division and was no longer independently traded.

  Transaction value. $16.6 billion announced acquisition value (2017)

  Source

• 2009

  Separate Mead Johnson from Bristol-Myers SquibbStrategy

  Background

  Bristol-Myers Squibb sought to concentrate on its biopharmaceutical business and treat Mead Johnson as a separate nutrition company.

  Action taken

  The companies implemented a stock-based separation that made Mead Johnson Nutrition an independent publicly traded company.

  Aftermath

  Mead Johnson operated independently and its common shares traded on the New York Stock Exchange until its acquisition by Reckitt in 2017.

  Source

• 2021

  Primavera Capital acquires Mead Johnson’s China nutrition business[1]Mead Johnsonen.wikipedia.org

  M&A

  Primavera Capital Group acquired the infant-formula and child-nutrition business of Mead Johnson Nutrition in China from Reckitt. Reckitt retained an 8 percent shareholding in the China business.

• 2021

  Reckitt agrees to sell its China infant-formula business to Primavera Capital Group[3]Reckitt agrees to sell its China infant-formula business to Primavera Capital Groupreckitt.com

  M&A

  Reckitt announced an agreement to divest its China infant-formula business to Primavera Capital Group. The transaction followed Reckitt's earlier acquisition of Mead Johnson Nutrition and represented a separation of the China infant-nutrition operation from the rest of Reckitt's global infant-formula business.

• 2017

  Reckitt Benckiser agrees to acquire Mead Johnson Nutrition[1]Mead Johnsonen.wikipedia.org

  M&A

  Reckitt Benckiser agreed to acquire Mead Johnson Nutrition in a cash transaction valued at approximately $16.6 billion.

• 2017

  Mead Johnson becomes part of Reckitt’s infant nutrition division[1]Mead Johnsonen.wikipedia.org

  M&A

  Following final regulatory approval, the acquisition by Reckitt was completed and Mead Johnson was integrated into Reckitt’s Infant Formula and Child Nutrition division.

• 2017

  Reckitt completed the acquisition of Mead Johnson Nutrition[2]Mead Johnson official websitemeadjohnson.com

  M&A

  Reckitt acquired Mead Johnson Nutrition, bringing the Enfamil business and the wider Mead Johnson nutrition portfolio into its consumer-health and nutrition operations.

• 2017

  Reckitt Benckiser completed the acquisition of Mead Johnson Nutrition[4]Reckitt Benckiser completed the acquisition of Mead Johnson Nutritionmeadjohnson.com

  M&A

  Mead Johnson Nutrition became part of Reckitt Benckiser following completion of the acquisition, expanding Reckitt's presence in infant and child nutrition.

• 2017

  Reckitt completes acquisition of Mead Johnson Nutrition[5]Reckitt completes acquisition of Mead Johnson Nutritionreckitt.com

  M&A

  Reckitt completed its acquisition of Mead Johnson Nutrition, bringing the Mead Johnson infant-nutrition business into the Reckitt group and changing the ownership context for Mead Johnson operations, including the China business.

• 2009

  Bristol-Myers announces plans to separate Mead Johnson[1]Mead Johnsonen.wikipedia.org

  M&A

  Bristol-Myers Squibb announced plans to separate Mead Johnson as part of a strategy to concentrate on its biopharmaceutical business.

• 2009

  Mead Johnson completes separation from Bristol-Myers Squibb[1]Mead Johnsonen.wikipedia.org

  M&A

  A stock-based separation made Mead Johnson Nutrition an independent publicly traded company after its period within Bristol-Myers Squibb.

1. 1Mead Johnsonen.wikipedia.org
2. 2Mead Johnson official websitemeadjohnson.com
3. 3Reckitt agrees to sell its China infant-formula business to Primavera Capital Groupreckitt.com
4. 4Reckitt Benckiser completed the acquisition of Mead Johnson Nutritionmeadjohnson.com
5. 5Reckitt completes acquisition of Mead Johnson Nutritionreckitt.com